Liquidia (NASDAQ:LQDA) Shares Gap Down - Time to Sell?

Liquidia Co. (NASDAQ:LQDA - Get Free Report)'s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $18.02, but opened at $14.65. Liquidia shares last traded at $14.03, with a volume of 3,223,525 shares traded.

Analyst Ratings Changes

LQDA has been the subject of several recent analyst reports. Wells Fargo & Company raised their price objective on shares of Liquidia from $20.00 to $23.00 and gave the company an "overweight" rating in a research note on Wednesday, May 28th. HC Wainwright increased their target price on shares of Liquidia from $29.00 to $35.00 and gave the company a "buy" rating in a report on Wednesday, May 28th. BTIG Research reissued a "buy" rating on shares of Liquidia in a research note on Tuesday, May 27th. Scotiabank upped their price target on Liquidia from $36.00 to $37.00 and gave the stock a "sector outperform" rating in a report on Wednesday, May 28th. Finally, Needham & Company LLC reaffirmed a "buy" rating on shares of Liquidia in a report on Monday, June 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Liquidia presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.67.

Liquidia Trading Down 4.3%

The business has a 50 day moving average of $15.05 and a 200-day moving average of $14.09. The stock has a market cap of $1.23 billion, a PE ratio of -8.81 and a beta of 0.04.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The company had revenue of $3.12 million during the quarter, compared to analysts' expectations of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, equities research analysts anticipate that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Insider Buying and Selling at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 2,450 shares of the business's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $13.67, for a total value of $33,491.50. Following the completion of the transaction, the insider now directly owns 263,152 shares in the company, valued at approximately $3,597,287.84. The trade was a 0.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Russell Schundler sold 5,964 shares of the stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $80,931.48. Following the transaction, the general counsel now directly owns 570,301 shares in the company, valued at approximately $7,738,984.57. This represents a 1.03% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 33,138 shares of company stock worth $450,233. Corporate insiders own 26.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Rhumbline Advisers boosted its position in shares of Liquidia by 6.0% in the first quarter. Rhumbline Advisers now owns 85,463 shares of the company's stock worth $1,261,000 after acquiring an additional 4,811 shares during the last quarter. Bluefin Capital Management LLC purchased a new position in Liquidia during the first quarter worth approximately $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Liquidia by 15.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company's stock valued at $1,796,000 after purchasing an additional 16,022 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Liquidia by 10.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company's stock valued at $12,703,000 after purchasing an additional 82,955 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Liquidia by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company's stock valued at $556,000 after buying an additional 1,700 shares during the period. Institutional investors and hedge funds own 64.54% of the company's stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).